 | | Vol. 10.36 – 15 September, 2021 |
| |
|
|
| Researchers generated Strap intestinal epithelial knockout mice by crossing mice containing floxed alleles of Strap with Villin-Cre mice. They used human colon cancer cell lines and human and mouse colon tumor-derived organoids for STRAP knockdown/knockout and overexpression experiments.
[Gastroenterology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors reported that Δ133p53β activity was regulated through an aggregation-dependent mechanism. Δ133p53β aggregates were observed in cancer cells and tumor biopsies.
[Nature Communications] |
|
|
|
| Investigators dissected the genetic and functional heterogeneity of human glioblastoma stem cells within patients by their innate responses to non-pathogenic mouse parvoviruses that were tightly restrained by cellular physiology.
[Cell Reports] |
|
|
|
| In silico analysis showed that epithelial membrane protein 3 (EMP3) was associated with favorable survival, and negatively regulated cell cycle S-phase. Loss and gain of function studies demonstrated that EMP3 inhibited breast cancer cell S-phage entry, DNA replication, DNA damage repair, and stem-like properties.
[Cell Death & Disease] |
|
|
|
| Researchers characterized the time-dependent impact of regadenoson on brain endothelial cell interactions and paracellular transport, using mouse and rat brain endothelial cells and tumor models.
[Molecular Cancer Research] |
|
|
|
| In vivo and in vitro metastasis assays confirmed miR-4721 promoted cell migration and invasion. Tumor spheroid formation assay, side population assay, and ALDEFLUOR assay verified miR-4721 regulated cancer stem cell-like properties.
[Journal of Translational Medicine] |
|
|
|
| The long non-coding RNA microarray analysis showed that the expression level of a tumor suppressive lncRNA maternally expressed 3 was significantly down-regulated in cadium-transformed cells, which was confirmed by further q-PCR analysis.
[Toxicology and Applied Pharmacology] |
|
|
|
| The regulatory role of miR-19b in colorectal CSCs and radiotherapy-resistant cells was determined using miRNA microarray analysis, and its prognostic value was probed using the TCGA database.
[Kaohsiung Journal of Medical Sciences] |
|
|
|
| CD133+ cells were sorted from prostate cancer cells using magnetic fluorescence cell sorting technology and were considered as CSCs.
[Cell Biology International] |
|
|
|
| Scientists investigated the expression of CD44 and CD133 in gastric cancer and non-neoplastic gastric mucosa. They used samples of primary gastric adenocarcinomas, metastatic lymph nodes, intestinal metaplasia, and histologically normal gastric tissues of surgical margins.
[Acta Histochemica] |
|
 |
|
|
|
| The authors comprehensively describe developments in the liver CSC field with emphasis on experiments utilizing single-cell transcriptomics to understand liver CSC heterogeneity, lineage-tracing and cell-ablation studies of liver CSCs, and the influence of the CSC niche and tumour microenvironment on liver cancer stemness, including interactions between CSCs and the immune system.
[Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| Investigators present the molecular pathways by which the miR 200 family manifests its effects on EMT, cancer stem cells, angiogenesis, anoikis, and the effects of tumor cell metastases.
[Molecular Biology Reports] |
|
|
|
|
| Novocure announced that it has entered into a clinical trial collaboration agreement with Roche, to develop Tumor Treating Fields together with Roche’s anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenocarcinoma.
[Novocure, GmbH] |
|
|
|
| PureTech Health plc announced that its Founded Entity, Vor Biopharma announced that the US FDA has granted Fast Track designation to VOR33, Vor’s lead engineered hematopoietic stem cell therapeutic candidate for the treatment of acute myeloid leukemia.
[PureTech Health plc] |
|
|
|
| The California Institute for Regenerative Medicine has awarded $31 million to three Stanford researchers to launch trials of treatments for common diseases. Four other Stanford researchers also received a total of $4.55 million.
[Stanford Medicine] |
|
|
|
|
|
|
|
| LIRCCS Candiolo Cancer Institute – Turin, Italy |
|
|
|
| | Houston Methodist Research Institute – Houston, Texas, United States |
|
|
|
| | CRUK Beatson Institute for Cancer Research – Glasgow, Scotland, United Kingdom |
|
|
|
| | University Hospital of Bern – Bern, Switzerland |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
